Cell Therapeutics, Inc.
Cell Therapeutics, Inc. granted U.S. patent for antitubulin agents with anti-cancer activity
Published in Law and Health Weekly, May 13th, 2006
CT-45099 is the first lead optimized agent from this class of compounds to advance into preclinical testing. The patent, owned by CTI's European subsidiary, Cell Therapeutics Europe S.r.l. (CTI-Europe), covers analogs of CT-45099 and will expire in April 2022. CT-45099 is protected by a U.S. and European patent already granted to CTI-Europe.
Unlike the marketed taxane-based cancer drugs, Taxol (paclitaxel) and Taxotere...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law and Health Weekly
More Articles from Law and Health Weekly
- Columbia University, New York
Cyclophilin A and TRIM5 alpha independently regulate HIV infectivity - DUA Pharmaceuticals, Inc.
DUSA Pharmaceuticals and New England Compounding Center announce favorable settlement - Federal University of Minas Gerais
Botulinum A toxin injected into gastric wall was safe treatment option for class III obesity - Grant Life Sciences, Inc.
DTL to develop, commercialize Grant's cervical cancer-diagnostic technology - Healthcare Coverage
Centers for Medicare and Medicaid Services (CMS) advises Niaspan is now Part D-eligible - Healthcare Coverage
Nine new health plans enter the Texas Medicare market, according to HealthLeaders-InterStudy - More from this issue of Law and Health Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
